Arabic Arabic English English French French German German
dark

Tevogen Bio™ Further Strengthens IP Portfolio With Additional Patent for Method of Preparing Its Investigational SARS-CoV-2 Specific T cell Therapy

Tevogen Bio, a clinical stage biotechnology company specializing in cell and gene therapies in oncology and viral infections, today announced that the U.S. Patent and Trademark Office (USPTO) has granted a new patent (No. 11,219,684) for the method of preparing COVID-19 peptide specific cytotoxic T cells (CTLs) for the treatment of COVID-19 infection. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

insitro Announces Leadership Team Expansion to Support Advancement of Machine Learning Enabled Drug Discovery and Development Efforts

Next Post

Cosmetic Facial Surgery: An Overview

Related Posts
Total
0
Share